ArticleAvicenna journal of phytomedicine
Protective effect of Henna (
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ulcerative colitis is a chronic recurrent inflammatory bowel disease of unknown etiology. The anti-inflammatory, immunomodulatory, and antioxidant characteristics of Henna Materials and Methods: In this research, the effect of HFO in a Wistar albino rat model of acetic acid (AA)-induced ulcerative colitis, was examined. The animals received daily oral administration of either normal saline (10 ml/kg), HFO (100, 400, and 1600 µl/kg), or dexamethasone (2 mg/kg) for 5 days. A single intracolonic injection of 2 ml of a 4% (v/v) acetic acid solution was used to induce colitis. The levels of myeloperoxidase (MPO) and tumor necrosis factor-alpha (TNF-α) were measured. Results: The administration of HFO at doses 400 and 1600 μl/kg showed a significant enhancement in the weight-to-length ratio of colon tissue in comparison to the control group. Furthermore, the increased amounts of HFO (400 and 1600 μl/kg) were associated with a significant reduction in ulcer severity, area, and index. However, examination of tissue samples revealed a decrease in the overall colitis index suggesting fewer inflammatory cells invaded the colonic regions of rats treated with HFO at doses of 400 and 1600 μl/kg. Moreover, the elevated MPO levels and TNF-α were significantly decreased following the administration of the fixed oil at these doses. Conclusion: These findings indicate that HFO could potentially decrease the manifestations of experimental colitis in a dose-dependent manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.